Does Rallies show 13F holders for ABT?

Yes. Rallies tracks hedge fund and 13F ownership data for ABT, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ABT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ABT. It does not provide personalized investment advice.

ABT (Abbott Laboratories) Stock Analysis - Hedge Fund Holdings

Abbott Laboratories (ABT) is a publicly traded Healthcare sector company. As of May 20, 2026, ABT trades at $88.27 with a market cap of $153.12B and a P/E ratio of 24.68. ABT moved -0.53% today. Year to date, ABT is -30.11%; over the trailing twelve months it is -34.63%. Its 52-week range spans $81.97 to $141.23. Analyst consensus is strong buy with an average price target of $120.24. Rallies surfaces ABT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ABT stock?

Hedge funds tracked by Rallies that own ABT include Maverick Capital, Pinebridge Investments, Panagora Asset, Berkshire Asset, and Redmile Group. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Abbott Laboratories.

ABT Key Metrics

Key financial metrics for ABT
Metric	Value
Price	$88.27
Market Cap	$153.12B
P/E Ratio	24.68
EPS	$3.59
Dividend Yield	0.63%
52-Week High	$141.23
52-Week Low	$81.97
Volume	5.95M
Avg Volume	0
Revenue (TTM)	$45.13B
Net Income	$6.28B
Gross Margin	56.26%

Top Hedge Funds Holding ABT

Maverick Capital holds 1.76M shares of ABT, changed +6939.12% as of Mar 31, 2026.
Pinebridge Investments holds 368.35K shares of ABT, changed -1.20% as of Sep 30, 2025.
Panagora Asset holds 314.65K shares of ABT, changed +1010.77% as of Mar 31, 2026.
Berkshire Asset holds 306.71K shares of ABT, changed +1.88% as of Mar 31, 2026.
Redmile Group holds 262.37K shares of ABT, changed -1.18% as of Mar 31, 2024.

Latest ABT News

Abbott’s Dividend Yield Hits Near-Decade High, Attracts Income Investors — May 12, 2026
Analyst Sees Abbott Undervaluation, Flags Recall Costs and China Slowdown as Temporary — May 9, 2026
Augment Acquires Merlin, Brings Alex Moazed Into $8 Trillion Distribution Market — Apr 29, 2026
Abbott's Ablation Catheter Posts 87% Arrhythmia-Free Rate, UltiSynq Lead Hits 99% Pacing Success — Apr 25, 2026
Coagulation Analyzer Market to Reach $7.87B by 2035 with 5.55% CAGR — Apr 22, 2026

Recent ABT Insider Trades

STARKS DANIEL J bought 10.00K (~$926.54K) on Apr 27, 2026.
Boudreau Philip P bought 2.20K (~$201.30K) on Apr 23, 2026.
Shroff Eric sold 709 (~$81.95K) on Mar 2, 2026.

ABT Analyst Consensus

20 analysts cover ABT: 0 strong buy, 16 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $120.24.

Common questions about ABT

Who owns ABT stock?: Hedge funds tracked by Rallies that own ABT include Maverick Capital, Pinebridge Investments, Panagora Asset, Berkshire Asset, and Redmile Group. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Abbott Laboratories.
Does Rallies show 13F holders for ABT?: Yes. Rallies tracks hedge fund and 13F ownership data for ABT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ABT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ABT. It does not provide personalized investment advice.